Shares of Stoke Therapeutics, Inc. (STOK) tumbled 6.08% in after-hours trading on Tuesday following the release of its third-quarter 2025 financial results. Despite reporting higher-than-expected revenue, the company's wider-than-anticipated loss per share appears to have disappointed investors.

Stoke Therapeutics reported Q3 revenue of $10.632 million, significantly surpassing the IBES estimate of $5.51 million. This represents a substantial 117.2% increase from the same quarter last year. However, the company posted a quarterly adjusted loss of 65 cents per share, which was larger than the mean analyst expectation of a 57 cents per share loss.

While Stoke Therapeutics highlighted its strong cash position of $328.6 million as of September 30, which is anticipated to fund operations through mid-2028, investors seemed more focused on the increased operating expenses. The company's operating expenses rose to $53.723 million for the quarter, with research and development expenses climbing to $96.2 million for the nine-month period, up from $65.7 million in the previous year. Despite the negative market reaction, Stoke Therapeutics emphasized ongoing progress in its clinical trials, including patient recruitment for the Phase 3 EMPEROR study of zorevunersen in the U.S., UK, and Japan.